Fresenius | FRE - Equity Capital And Reserves


Fresenius reported EUR20.51B in Equity Capital and Reserves for its fiscal quarter ending in September of 2026.





Equity Capital And Reserves Change Date
Akzo Nobel EUR 4.85B 0 Sep/2026
Alcon AG USD 21.6B 538M Jun/2026
AstraZeneca USD 51.73B 1.43B Sep/2026
BASF EUR 37.73B 1.41B Sep/2026
Bayer EUR 29.18B 533M Sep/2026
Beiersdorf EUR 9.01B 408M Jun/2026
DaVita Healthcare Partners USD -591.09M 174.01M Sep/2026
Demant DKK 11.24B 1.4B Jun/2026
E.ON EUR 21.22B 7.6B Jun/2026
Essilor EUR 39.22B 329M Jun/2026
Fresenius EUR 20.51B 810M Sep/2026
Fresenius Medical Care EUR 13.76B 226.23M Sep/2026
Getinge SEK 30.94B 2.06B Jun/2026
Givaudan CHF 4.54B 430M Dec/2025
GlaxoSmithKline GBP 18.75B 1.11B Sep/2026
GN Store Nord DKK 10.51B 241M Sep/2026
GRIFOLS EUR 5.79B 2.19B Sep/2026
Hikma Pharmaceutical USD 2.59B 42M Dec/2025
Lonza CHF 9.13B 513M Dec/2025
Merck EUR 30.17B 430M Jun/2026
Novartis USD 37.23B 4.72B Sep/2026
Philips EUR 11.61B 133M Sep/2026
Roche Holding CHF 32.69B 1.11B Jun/2026
RWE EUR 39.62B 3.2B Jun/2026
Sanofi EUR 72.88B 3.31B Sep/2026
Smith & Nephew USD 5.18B 356M Jun/2026